$160.46
-1.04 (-0.64%)
AZN News30 articles
Bristol Myers Soars on AstraZeneca Takeover Talks, But Market Cap Math Raises Red Flags
Bristol Myers Squibb (BMY) surged 8% on AstraZeneca (AZN) merger speculation, but combined market cap fell $6.2B. Strong Q2 results and raised guidance bolster standalone case.
AstraZeneca slides on Bristol Myers tie-up talks; $5B value gap emerges
AstraZeneca shares dropped 5% on report of early merger talks with Bristol Myers Squibb, which gained 6% premarket. Combined market value fell about $5.2 billion.
Bristol Myers Squibb at Crossroads as AstraZeneca Merger Talks Surface
Bristol Myers Squibb shares rose 5.2% last week after strong Q2 earnings, but a reported $400B merger approach from AstraZeneca puts the stock in focus Monday.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Tempus AI Dips After Hours Despite Q2 Beat; Focus Shifts to H2 Profitability
Tempus AI slipped 2.6% in after-hours trade despite a slight Q2 revenue beat and raised full-year guidance, as markets scrutinize the company's ability to ramp margins in the second half.
FTSE 100 Gains Trimmed as Oil Price Slide Spurs Sector Rotation
London's FTSE 100 trimmed most of its early gains as a sharp drop in oil prices fueled a sector rotation, benefiting airlines and mid-caps while pressuring energy majors.
FTSE 100 Gains as Oil Earnings and BoE Decision Loom
The FTSE 100 closed at 10,736.23, up 1.28% for the week. Energy is expected to contribute 62% of incremental earnings growth for the STOXX 600, with the BoE widely anticipated to hold rates steady.
GSK faces £3.6B revenue gap ahead of Tuesday strategy update
GSK faces a £3.63 billion revenue gap versus its 2031 target of £40 billion ahead of its strategy update on July 28. The shortfall persists despite oncology growth.
SK Hynix Market Cap Plunges 114 Trillion Won Amid Legal Woes and Tech Sell-Off
SK Hynix shares tumbled 8.34% on Friday, erasing 114 trillion won in market value, as a court order against chairman Chey Tae-won added to a broader tech rout.
Aviva's 6% Yield and Strategic Growth Drive UK Market Focus
Aviva offers a 6% dividend yield with rising payouts, while Middle East tensions boost energy stocks and gold prices. U.S. futures edge up ahead of tech earnings.
Attovia Therapeutics Files IPO to Challenge Dupixent and Nemluvio
Attovia Therapeutics has filed for an IPO to raise capital for developing rival treatments to Sanofi and Regeneron's Dupixent and Galderma's Nemluvio.
FTSE 100 Edges Lower as AstraZeneca, HSBC Drag; Energy Stocks Rally
The FTSE 100 dipped 0.1% to 10,486 as AstraZeneca and HSBC losses outweighed gains from BP and Shell. Housing stocks rose on Help to Buy rumors.
Pfizer Gains FDA Nod for Padcev Combo, Yet Stock Remains Flat
Pfizer's Padcev/Keytruda combo gets FDA approval for bladder cancer, but the stock dipped 0.33%. Wall Street remains cautious about revenue impact.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Vodafone and easyJet Deal Surge Lifts FTSE
Vodafone and easyJet shares surged on separate deal announcements, lifting the FTSE 100 and FTSE 250 while most stocks remained flat.
Ionis Plunges 23% After Wainua Misses Key Goal in Heart Disease Trial
Ionis stock tumbled 23% after Wainua missed its primary endpoint in a major heart disease trial, erasing $3.2 billion in market value. The setback shifts attention to the company's TRYNGOLZA launch.
FTSE 100 Dips as AstraZeneca Drug Trial Disappoints
London's FTSE 100 fell as AstraZeneca dropped nearly 9% on a trial miss. The FTSE 250 rose, splitting the market. Oil and Middle East risks persist.
Novo Nordisk Shares Rally as Healthcare Sector Lifts OMXC25
Novo Nordisk B shares rose 5% to 294.4 Danish crowns, leading the OMXC25 higher as healthcare stocks gained. The rally came amid a cyber incident and ongoing competition with Eli Lilly in oral obesity drugs.
G7 Leaders Debate AI Model Access Amid OpenAI's $1T IPO Plan and Rising China Competition
G7 leaders debate AI model access as OpenAI files for a $1T IPO. Anthropic restricts models, China boosts local AI, and cybersecurity deals surge.
GSK Acquires Nuvalent for $10.6B in Oncology Push Ahead of HIV Patent Cliff
GSK buys Nuvalent for $10.6B, paying a 40% premium, to strengthen its oncology portfolio and offset upcoming HIV drug patent losses.
Novo Nordisk Shares Slide 4% Despite Wegovy Pill Prescriptions Surpassing 3 Million
Novo Nordisk shares dropped over 4% despite the Wegovy pill hitting 3 million U.S. prescriptions, as investors weighed profit margins against fierce competition from Eli Lilly and AstraZeneca.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Abivax shares drop despite positive Phase 3 results for ulcerative colitis drug
Abivax shares plunged 33.7% after hours despite obefazimod achieving clinical remission in over 50% of patients in a Phase 3 trial. The company plans to submit an FDA application in late Q4 2026.
AIM ImmunoTech Surges on Early Pancreatic Cancer Trial Enrollment Completion
AIM ImmunoTech shares surged over 100% after its Phase 2 pancreatic cancer trial reached final enrollment ahead of schedule, with the primary endpoint readout set for December 2026.
FTSE 100 Drops as Oil Surge on Iran Tensions Ends Winning Streak
London's FTSE 100 dropped 0.97% at the open Thursday, ending an eight-session winning streak as Brent crude jumped 3.6% on renewed U.S.-Iran tensions, triggering a broad risk-off move.
Hormuz Crisis Looms Over Oil Markets as Physical Prices Surge
Brent crude slipped to $108.17 on Friday after Iran proposed talks, but the Strait of Hormuz remains disrupted, and physical crude grades trade near $130, signaling further price spikes ahead.
FTSE 100 Slides as Healthcare Stocks Weigh Despite Earnings Beats
The FTSE 100 slipped 0.6% as healthcare giants AstraZeneca and GSK declined despite topping profit forecasts, while Lloyds Banking Group's profit jump failed to lift sentiment.
Meta's Q1 Earnings to Gauge AI Investment Payoff Amid Rising Costs
Meta Platforms will announce first-quarter financial results on April 29, as investors assess whether advertising gains can sustain the company's aggressive artificial intelligence investments.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
Cocoa Prices Plunge on European Demand Slump, Asian Markets Mixed
Cocoa prices tumbled over 3% after weak European demand data, while Asian markets diverged with Hong Kong falling and India's Sensex gaining.